Identification of Novel Loci Involved in Adalimumab Response in Crohn’s Disease Patients Using Integration of Genome Profiling and Isoform-Level Immune-Cell Deconvoluted Transcriptome Profiling of Colon Tissue
Crohn’s disease is a consequence of dysregulated inflammatory response to the host’s microbiota. Although anti-TNF treatment improves the quality of the patient’s life, a large proportion of patients lose response to the treatment. The past decade of research has led to a continuum of studies showca...
Main Authors: | Mario Gorenjak, Gregor Jezernik, Martina Krušič, Pavel Skok, Uroš Potočnik |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/9/1893 |
Similar Items
-
MIF Variant rs755622 Is Associated with Severe Crohn’s Disease and Better Response to Anti-TNF Adalimumab Therapy
by: Gregor Jezernik, et al.
Published: (2023-02-01) -
Adalimumab and azathioprine in the prevention of postoperative crohn’s disease recurrence
by: A. V. Poletova, et al.
Published: (2020-10-01) -
Leukocytoclastic Vasculitis Associated with Adalimumab Therapy for Crohn’s Disease
by: Lankai Cathy Xu, et al.
Published: (2023-03-01) -
Crohn’s Disease Associated Pyoderma Gangrenosum Treated with Adalimumab
by: Despoina Kakagia, et al.
Published: (2012-03-01) -
Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease
by: Carlos Taxonera, et al.